Stephen L Lewis1, Sandro Porceddu, Naoki Nakamura, David A Palma, Simon S Lo, Peter Hoskin, Drew Moghanaki, Steven J Chmura, Joseph K Salama. 1. *Department of Radiation Oncology, Duke University Medical Center, Durham, NC †Princess Alexandra Hospital, Brisbane, Qld, Australia ‡Department of Radiation Oncology, St. Luke's International Hospital, Akashicho, Chuouku, Tokyo, Japan §London Health Sciences Centre, London, ON, Canada ∥Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH ¶Mount Vernon Cancer Centre, Northwood, UK #Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA **Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.
Abstract
PURPOSE: Stereotactic body radiotherapy (SBRT) is often used to treat patients with oligometastases (OM). Yet, patterns of SBRT practice for OM are unknown. Therefore, we surveyed radiation oncologists internationally, to understand how and when SBRT is used for OM. METHODS: A 25-question survey was distributed to radiation oncologists. Respondents using SBRT for OM were asked how long they have been treating OM, number of patients treated, organs treated, primary reason for use, doses used, and future intentions. Respondents not using SBRT for OM were asked reasons why SBRT was not used and intentions for future adoption. Data were analyzed anonymously. RESULTS: We received 1007 surveys from 43 countries. Eighty-three percent began using SBRT after 2005 and greater than one third after 2010. Eighty-four percent cited perceived treatment response/durability as the primary reason for using SBRT in OM patients. Commonly treated organs were lung (90%), liver (75%), and spine (70%). SBRT dose/fractionation schemes varied widely. Most would offer a second course to new OM. Nearly all (99%) planned to continue and 66% planned to increase SBRT for OM. Of those not using SBRT, 59% plan to start soon. The most common reason for not using SBRT was lack of clinical efficacy (48%) or lack of necessary image guidance equipment (34%). CONCLUSIONS: Radiation oncologists are increasingly using SBRT for OM. The main reason for not using SBRT for OM is a perceived lack of evidence demonstrating clinical advantages. These data strengthen the need for robust prospective clinical trials (ongoing and in development) to demonstrate clinical efficacy given the widespread adoption of SBRT for OM.
PURPOSE: Stereotactic body radiotherapy (SBRT) is often used to treat patients with oligometastases (OM). Yet, patterns of SBRT practice for OM are unknown. Therefore, we surveyed radiation oncologists internationally, to understand how and when SBRT is used for OM. METHODS: A 25-question survey was distributed to radiation oncologists. Respondents using SBRT for OM were asked how long they have been treating OM, number of patients treated, organs treated, primary reason for use, doses used, and future intentions. Respondents not using SBRT for OM were asked reasons why SBRT was not used and intentions for future adoption. Data were analyzed anonymously. RESULTS: We received 1007 surveys from 43 countries. Eighty-three percent began using SBRT after 2005 and greater than one third after 2010. Eighty-four percent cited perceived treatment response/durability as the primary reason for using SBRT in OM patients. Commonly treated organs were lung (90%), liver (75%), and spine (70%). SBRT dose/fractionation schemes varied widely. Most would offer a second course to new OM. Nearly all (99%) planned to continue and 66% planned to increase SBRT for OM. Of those not using SBRT, 59% plan to start soon. The most common reason for not using SBRT was lack of clinical efficacy (48%) or lack of necessary image guidance equipment (34%). CONCLUSIONS: Radiation oncologists are increasingly using SBRT for OM. The main reason for not using SBRT for OM is a perceived lack of evidence demonstrating clinical advantages. These data strengthen the need for robust prospective clinical trials (ongoing and in development) to demonstrate clinical efficacy given the widespread adoption of SBRT for OM.
Authors: Laura A Dawson; Kathryn A Winter; Alan W Katz; Michael C Schell; James Brierley; Yuhchyau Chen; Neil Kopek; Christopher H Crane; Christopher G Willett Journal: Pract Radiat Oncol Date: 2019-02-27
Authors: Hania A Al-Hallaq; Steven Chmura; Joseph K Salama; Kathryn A Winter; Clifford G Robinson; Thomas M Pisansky; Virginia Borges; Jessica R Lowenstein; Susan McNulty; James M Galvin; David S Followill; Robert D Timmerman; Julia R White; Ying Xiao; Martha M Matuszak Journal: Pract Radiat Oncol Date: 2016-05-20
Authors: J M Laba; S Senan; D Schellenberg; S Harrow; L Mulroy; S Senthi; A Swaminath; N Kopek; J R Pantarotto; L Pan; A Pearce; A Warner; A V Louie; D A Palma Journal: Curr Oncol Date: 2017-12-20 Impact factor: 3.677